ECSP045114A - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Info

Publication number
ECSP045114A
ECSP045114A EC2004005114A ECSP045114A ECSP045114A EC SP045114 A ECSP045114 A EC SP045114A EC 2004005114 A EC2004005114 A EC 2004005114A EC SP045114 A ECSP045114 A EC SP045114A EC SP045114 A ECSP045114 A EC SP045114A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hgh
Prior art date
Application number
EC2004005114A
Other languages
Spanish (es)
Inventor
Rory F Finn
Wei Liao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP045114A publication Critical patent/ECSP045114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una modificación química de la hormona de crecimiento humana (hGH) y a variantes agonistas de la misma mediante la cual se pueden cambiar las propiedades químicas y/o fisiológicas de la hGH. La hGH PEGilada puede tener una mayor duración de residencia en plasma, una menor velocidad de aclaramiento, mejor estabilidad, menos antigenicidad o una combinación de estas característicasThe present invention relates to a chemical modification of human growth hormone (hGH) and agonist variants thereof by which the chemical and / or physiological properties of hGH can be changed. PEGylated hGH may have a longer residence duration in plasma, a lower clearance rate, better stability, less antigenicity or a combination of these characteristics

EC2004005114A 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES ECSP045114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
ECSP045114A true ECSP045114A (en) 2004-07-23

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005114A ECSP045114A (en) 2001-11-20 2004-05-20 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20070072924A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PT3025726T (en) * 2002-01-18 2020-01-09 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USES OF THE SAME
JP4764630B2 (en) 2002-09-09 2011-09-07 ネクター セラピューティックス Water-soluble polymer alkanal
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008525032A (en) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Methods for expressing and purifying recombinant human growth hormone
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
HRP20110404T1 (en) * 2005-11-08 2011-08-31 Ambrx Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
KR101423898B1 (en) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
JP5458416B2 (en) * 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド Double-chain polyethylene glycolated growth hormone, process for its production and use thereof
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof
JP5639585B2 (en) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション Peptide-polymer conjugate
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
JP5816097B2 (en) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
PL2525834T3 (en) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND
JP2013533217A (en) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド PEGylated C-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
ES2841123T3 (en) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Growth hormone compound formulation
AU2015342908B2 (en) 2014-11-06 2021-06-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
KR102608645B1 (en) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 Novel polymeric hgh prodrugs
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
KR102152437B1 (en) 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 Long acting adrenomedulin derivatives
JP7524206B2 (en) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス Long-acting growth hormone formulation with superior efficacy to daily somatropin - Patent Application 20070123333
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 PEGylated long-acting growth hormone and its preparation method and medical application

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (en) * 1990-05-04 1998-05-01 American Cyanamid Co STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE.
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE455171T1 (en) * 1995-09-21 2010-01-15 Genentech Inc VARIANTS OF HUMAN GROWTH HORMONE
ATE375363T1 (en) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) * 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (en) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス Improved growth hormone molecule

Also Published As

Publication number Publication date
AU2002356990A1 (en) 2003-06-10
WO2003044056A2 (en) 2003-05-30
CO5580794A2 (en) 2005-11-30
AP2004003050A0 (en) 2004-06-30
EA008505B1 (en) 2007-06-29
OA13063A (en) 2006-11-10
MA27544A1 (en) 2005-10-03
WO2003044056A3 (en) 2003-08-21
HUP0500997A2 (en) 2007-11-28
KR20070072924A (en) 2007-07-06
RS53104A (en) 2006-10-27
EP1453859A2 (en) 2004-09-08
NO20042182L (en) 2004-08-11
EA200400565A1 (en) 2005-06-30
JP2006321808A (en) 2006-11-30
GEP20063860B (en) 2006-06-26
KR20050044858A (en) 2005-05-13
TNSN04090A1 (en) 2006-06-01
JP2005525302A (en) 2005-08-25
CA2467731A1 (en) 2003-05-30
PL374354A1 (en) 2005-10-17
ZA200403907B (en) 2007-12-27
EA200700431A1 (en) 2008-02-28
MXPA04004809A (en) 2004-08-11
HRP20040448A2 (en) 2006-02-28
IL162031A0 (en) 2005-11-20
BR0214451A (en) 2006-05-30
CN1608079A (en) 2005-04-20
IS7268A (en) 2004-05-17

Similar Documents

Publication Publication Date Title
EP1196444B8 (en) Exendin-4 conjugates and their medical use
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
NO20042182L (en) Chemically modified growth hormone conjugates
EP1682210A4 (en) Implantable medical devices with enhanced visibility, mechanical properties and biocompatibility
AP2003002918A0 (en) Pulmonary administration of chemically modified insulin.
DE602004017252D1 (en) Body care compositions Compositions containing structured conditioner premix
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
NO20053556D0 (en) Polymer conjugates of interferon-beta with enhanced biological potency.
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002245413A1 (en) Athletic clothing with sting reduction padding
MXPA03007802A (en) Composition improving age-related physiological deficits and increasing longevity.
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2003051389A3 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
DE10158785B8 (en) Medical implant
DE60211432D1 (en) Water-dispersible, modified starch-containing agricultural agents with altered physical form
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
PL1522312T3 (en) Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin.
AU2003223679A1 (en) Implantable lead with improved distal tip
HUP0401289A3 (en) Cyclic ketones as blocking agents
BRPI0412803A (en) unglycosylated human alpha-fetoprotein, production methods and uses thereof
WO2004039326A3 (en) Propofol with cysteine
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
BRPI0313645A2 (en) inhalation compositions with high drug ratios.
TR200601608T1 (en) Long-acting compositions comprising an avermectin combination.
ZA200205880B (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith.